NX001

**NX001** is a synthetic kidney growth factor peptide developed by NephRx Corporation for the prevention of delayed graft function (DGF) in renal transplant patients. It promotes renal repair by stimulating kidney cell growth, migration, and protection from injury in preclinical models of acute renal failure, demonstrating good safety and efficacy without toxicity. The peptide received orphan drug designation from the FDA and advanced to a Phase I clinical trial involving single ascending doses in healthy volunteers to assess safety and pharmacokinetics, with plans for Phase II testing in transplant patients.[1][3][5][6]